Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors

RMD Open. 2022;8(2):e002571 doi: 10.1136/rmdopen-2022-002571

Weitz, et al. analyse 291 protein biomarkers and three genetic markers and do not identify a clear mechanistic explanation for higher rates of venous thromboembolism (VTE) with tofacitinib in the ORAL Surveillance study.

Following the increased frequency of pulmonary embolism with tofacitinib 10 mg BD versus TNFi, and increased overall mortality, compared with tofacitinib 5 mg BD or TNFi, in the ORAL Surveillance study, this exploratory post hoc analysis examined whether biomarkers explained the associations of tofacitinib versus TNFi with VTE.